Inhibition of the Protease of Human Immunodeficiency Virus Blocks Replication and Infectivity of the Virus in Chronically Infected Macrophages

Journal of Infectious Diseases

Volumn 168, Issue 5, 1993, Pages 1148-1156

  Perno, Carlo Federico ^a,b,c   Bergamini, Alberto ^a,b,c   Pesce, Caterina D ^a,b,c   Milanese, Giuseppe ^a,b,c   Capozzi, Marcella ^a,b,c   Aquaro, Stefano ^a,b,c   Thaisrivongs, Suvit ^a,b,c   Tarpley, W Gary ^a,b,c   Zon, Gerald ^a,b,c   D’Agostini, Cartesio ^a,b,c   Rocchi, Giovanni ^a,b,c   Garaci, Enrico ^a,b,c   Calió, Raffaele ^a,b,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b PFIZER INC   (United States)

^c ILLUMINA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (NAPHTHOXYACETYL)HISTIDYL(5 AMINO 6 CYCLOHEXYL 3,4 DIHYDROXY 2 ISOPROPYLHEXANOYL)ISOLEUCINE N (2 PYRIDYLMETHYL)AMIDE; ALPHA INTERFERON; ANTISENSE OLIGODEOXYNUCLEOTIDE; PROTEINASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; PRIORITY JOURNAL; PROTEINASE INHIBITION; VIRUS INFECTIVITY; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; COMPARATIVE STUDY; GENES, REV; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMAN; MACROPHAGES; OLIGODEOXYRIBONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; OLIGOPEPTIDES; SUPPORT, NON-U.S. GOV'T; THIONUCLEOTIDES; TRANSCRIPTION, GENETIC; VIRULENCE; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0027430147     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/168.5.1148     Document Type: Article

References (63)

1. Yarchoan R, Klecker RW, Weinhold KJ, Administration of 3'azido- 3'-deoxythymidine, an inhibitor ofHTLV-III/LAV replication, to patients with AIDS or AIDS-related complex, Lancet 1986; 1: 575-82.
2. Fischl MA, Richman DD, Grieco MH, The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex, N Engl 1 Med 1987; 317: 185-90.
3. Yarchoan R, Mitsuya H, Thomas RV, In vivo activity against HIV and favorable toxicity profile of 2', 3'-dideoxyinosine, Science 1989; 245: 412-7.
4. Mitsuya H, Weinhold KJ, Furman PA, 3'-azido-3'-deoxythymidine (BW A509U): An antiviral agent that inhibits the infectivity and cytopathic effect of human T Iymphotropic virus type III-lymphadenopathy associated virus in vitro, Proc Natl Acad Sci USA 1985; 82: 7096-101.
5. Furman PA, Fyfe JA, St Clair M, Phosphorylation of3'-azido-3'deoxythymidine and selective interaction ofthe 5'-triphosphate with human immunodeficiency virus reverse transcriptase, Proc Natl Acad Sci USA 1986; 83: 8333-7.
6. Yarchoan R, Pluda JM, Perno CF, Mitsuya H, Broder S, Antiretroviral therapy of HIV infection: Current strategies and challenges for the future, Blood 1991; 78: 859-84.
7. Mitsuya H, Yarchoan R, Broder S, Molecular targets for AIDS therapy, Science 1990; 249: 1533-44.
8. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, Popovic M, The role of mononuclear phagocytes in HTLV-III/LAV infection, Science 1986; 233: 215-9.
9. Ho DD, Rota TR, Hirsch MS, Infection ofmonocytes/macrophages by human T-Iymphotropic virus type III, J C1in Invest 1986; 77: 1712-5.
10. Perno CF, Yarchoan R, Cooney DA, Inhibition of human immunodeficiency virus (HIV-I /HTLV-IIIBa-d replication in fresh and cultured human peripheral blood monocytes/rnacrophages by azidothymidine and related 2', 3'-dideoxynucleosides, J Exp Med 1988; 168: 1111-25.
11. Koenig S, Gendelman HE, Orenstein JM, Detection of AIDS virus in macro phages in brain tissues from AIDS patients with encephalopathy, Science 1986; 233: I089-92.
12. Vazeux R, Brousse N, Jarry A, AIDS subacute encephalitis, Identification of HIV-infected cells, Am J Pathol 1986; 126: 403-10.
13. Meltzer MS, Skillman DR, Gomatos PJ, Kalter DC, Gendelman HE, Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection, Annu Rev Immunol 1990; 8: 16994.
14. Armstrong lA, Horn P, Follicular dendritic cells and virus-like particles in AIDS-related lymphadenopathy, Lancet 1984; 2: 370-2.
15. Tschachler E, Groh V, Popovic M, Epidermal Langerhans cells: A target for HTLV-III/LAV infection, J Invest Dermatol 1987; 88: 233-41.
16. Meltzer MS, Nakamura M, Hanse BD, Turpin JA, Kalter DC, Gendelman HE, Macrophages as susceptible targets for HIV infection, persistent viral reservoir in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease, AIDS Res Hum Retroviruses 1990; 6: 967-75.
17. McElrath MJ, Pruett JE, Cohn ZA, Mononuclear phagocytes of blood and bone marrow: Comparative roles as viral reservoirs in human immunodeficiency virus type I infection, Proc Natl Acad Sci USA 1989; 86: 675-9.
18. Mattern CF, Murray K, Jensen A, Farzadegan H, Pang J, Modlin JF, Localization of human immunodeficiency virus core antigen in term human placentas, Pediatrics 1992; 89: 207-9.
19. Innocenti P, Ottman M, Morand P, Leclercq P, Seigneurin JM, HIV-I in monocytes: Frequency of detection of proviral DNA using PCR and comparison with the total CD4 count, AIDS Res Hum Retroviruses 1992; 8: 261-8.
20. Perno CF, Baseler MW, Broder S, Yarchoan R, Infection ofmonocytes by human immunodeficiency virus type-I is blocked by inhibitors of CD4-gp 120 binding, even in the presence ofenhancing antibodies, J Exp Med 1990; 171: 1043-56.
21. Perno CF, Cooney DA, Currens MJ, Ability of anti-HIV agents to inhibit HIV replication in rnonocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HlV antibodies, AIDS Res Hum Retroviruses 1990; 6: 1051-8.
22. Crowe S, Mills J, Kirihara J, Boothman J, Marshall JA, McGrath MS, Full-length recombinant CD4 and recombinant gp 120 inhibit fusion between HIV-infected macrophages and uninfected CD4-expressing T-Iymphoblastoid cells, AIDS Res Hum Retroviruses 1990; 6: 1031-7.
23. Sato H, Orenstein J, Dimitrov D, Martin M, Cell-to-cell spread ofHIVI occurs within minutes and may not involve the participation of virus particles, Virology 1992; 186: 712-24.
24. Schuitemaker H, Koot M, Kootstra NA, Biological phenotype of human immunodeficiency virus type I clones at different stages of infection: Progression ofdisease is associated with a shift from monocytotropic to T-cell-tropic virus population, J Virol 1992; 66: 135-460.
25. Hwang SS, Bojle TJ, Lyerly HK, Cullen BR, Identification of the envelope V3 loop as the primary determinant ofT-cell tropism in HIV-I, Science 1991; 253: 71-4.
26. Koyanagi Y, O'Brien WA, Zhao JQ, Golde DW, Gasson IC, Chen ISY, Cytokines alter production of HIV-I from primary mononuclear phagocytes, Science 1988; 241: 1673-7.
27. Brinkmann R, Schwinn A, Narayan O, Zink C, Kreth HW, Human immunodeficiency virus infection in microglia: Correlation between cells infected in the brain and cells cultured from infectious brain tissue, Ann Neurol 1992; 31: 361-5.
28. Gendelman HE, Orenstein JM, Martin MA, Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor I-treated monocytes, J Exp Med 1988; 167: 1428-40.
29. Perno CF, Yarchoan R, Cooney DA, Replication ofhuman immunodeficiency virus in monocytes: Granulocyte-macrophage colony stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2', 3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine, J Exp Med 1989; 169: 933-51.
30. Perno CF, Cooney DA, Gao WY, Effects ofbone marrow stimulatory cytokines on HIV replication and the antiviral activity of dideoxynucleosides in cultures of rnonocyte/macrophages, Blood 1992; 80: 995-1003.
31. Poli G, Kinter A, Justement JS, Tumor necrosis factor alfa functions in an autocrine manner in the induction ofhuman immunodeficiency virus expression, Proc Natl Acad Sci USA 1990; 87: 782-5.
32. Kazazi F, Mathjis JM, Chang J, Recombinant interleukin-4 (IL-4) stimulates human immunodeficiency virus production by infected monocytes and macrophages, J Gen Virol 1992; 73: 941-9.
33. Perno CF, Yarchoan R, Balzarini J, Different pattern ofactivity of inhibitors ofthe human immunodeficiency virus in lymphocytes and monocyte/rnacrophages, Antiviral Res 1992; 17: 289-304.
34. Debouck C, The HIV-I protease as a therapeutic target for AIDS, AIDS Res Hum Retroviruses 1992; 8: 153-64.
35. Ashorn P, McQuade TJ, Thaisrivongs S, Tomasselli AG, Tarpley WG, Moss B, An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection, Proc Natl Acad Sci USA 1990; 87: 7472-6.
36. Martin JA, Recent advances in the design of HIV proteinase inhibitors, Antiviral Res 1992; 17: 265-78.
37. Kageyama S, Weinstein IN, Shirasaka T, In vitro inhibition of human immunodeficiency virus (HIV) type I replication by C2 symmetry- based HlV protease inhibitors as single agents or in combinations, Antimicrob Agents Chemother 1992; 36: 926-33.
38. Kohl H, Emini E, Schleif W, Active human immunodeficiency virus protease is required for viral infectivity, Proc Natl Acad Sci USA 1988; 85: 4686-90.
39. Pearl L, Taylor W, A structural model of the retroviral proteases, Nature 1987; 329: 351-4.
40. Popovic M, Sangaradharan MG, Read E, Gallo RC, Detection, isolation, and continuous production of cytopathic retroviruses (HTLVlll) from patients with AIDS and pre-AIDS, Science 1984; 224: 497-501.
41. Matsukura M, Zon G, Shinozuka K, Synthesis of phosphorothioate analogues of oligodeoxynucleosides and its antiviral activity against human immunodeficiency virus (HIV), Gene 1988; 72: 343-7.
42. Matsukura M, Zon G, Shinozuka K, Regulation of viral expression of HIV (human immunodeficiency virus) in vitro by antisense phosphorothioate oligodeoxynucleosides against rev (art/trs) in chronically infected cells, Proc Natl Acad Sci USA 1989; 86: 4244-8.
43. Zon G, Geiser TG, Phosphorothioate oligonucleotides: Chemistry, purification, analysis, scale-up and future directions, Anticancer Drug Des 1991; 6: 539-68.
44. Kibler-Herzog L, Zon G, Uznanski B, Whittier G, Wilson WD, Duplex stabilities of phosphorothioate, methylphosphonate, and RNA analogs of two DNA 14-mers, Nucleic Acids Res 1991; 19: 2979-86.
45. Chin DJ, Green GA, Zon G, Szoka FC, Straubinger RM, Rapid nuclear accumulation of injected oligodeoxyribonucleotides, New Biol 1990; 2: 1091-100.
46. Pauwels R, Balzarini J, Baba M, Rapid and automated tetrazoliurn- based colorimetric assay for the detection of anti-HlV compounds, J Virol Methods 1988; 20: 309-21.
47. Bergamini A, Perno CF, Capozzi M, A tetrazolium-based colorimetric assay for quantification of HIV-induced cytopathogenicity in monocyte-macrophages exposed to macrophage-colony stimulating factor, J Virol Methods 1992; 40: 275-86.
48. Sambrook J, Fritsch EF, Maniatis T, Molecular cloning: A laboratory manual, 2nd ed, Cold Spring Harbor, NY: Cold Spring Harbor laboratory Press, 1989: II, 31-3.
49. Kellogg DE, Kwok S, Detection ofhuman immunodeficiency virus, In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, eds, PCR protocols: A guide to methods and applications, San Diego: Academic Press, 1990: 337-47.
50. Jacobsen H, Ahlborn-Laake L, Gugel R, Mous J, Progression of early steps of human immunodeficiency virus type I replication in the presence of an inhibitor of viral protease, J Virol 1992; 66: 5087-91.
51. Matsukura M, Shinozuka K, Zon G, Phosphorothioate analogs of oligodeoxynucleotides: Inhibitors ofreplication and cytopathic effectof human immunodeficiency virus, Proc Natl Acad Sci USA 1987; 84: 7706-10.
52. Kinchington D, Galpin S, Jaroszewski JW, Ghosh K, Subasinghe C, Cohen JS, A comparison ofgag, pol, and rev antisense oligodeoxynuc1eotides as inhibitors of HIV-1, Antiviral Res 1992; 17: 53-62.
53. Lisziewicz J, Sun D, Klotman M, Agrawal S, Zamecnik P, Gallo R, Specific inhibition of human immunodeficiency virus type I replication by antisense oligonucleotides: An in vitro model for treatment, Proc Natl Acad Sci USA 1992; 89: 11209-13.
54. Dhawan S, Toro LA, Jones BE, Meltzer MS, Interactions between HIVinfected monocytesand the extracellular matrix: HIV-infected monocytes secrete neutral metalloproteases that degrade basement membrane protein matrices, J Leukoc Bioi 1992; 52: 244-8.
55. Dhawan S, Vargo M, Meltzer MS, Interactions between HIV-infected monocytes and the extracellular matrix, Increased capacity of HIVinfected monocytes to adhere to and spread on extracellular matrix associated with changes in extent of virus replication and cytopathic effect in infected cells, J Leukoc Biol 1992; 51: 62-9.
56. Adams LD, Tomasselli AG, Robbins P, Moss B, Heinrikson RL, HIV-I protease cleaves actin during acute infection of human T-Iymphocytes, AIDS Res Hum Retroviruses 1992; 8: 291-5.
57. Tomasselli AG, Howe WJ, Hui JO, et al, Calcium-free calmodulin is a substrate of proteases from human immunodeficiency viruses I and 2, Proteins Struct Funct Genet 1991; 10: 1-9.
58. Tomasselli AG, Hui JO, Adams LD, et al, Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin-I tl as substrates of the protease from human immunodeficiency virus, J Bioi Chern 1991; 266: 14548-53.
59. Giulian D, Vaca K, Noonan CA, Secretion of neurotoxins by mononuclear phagocytes infected with HIV-1, Science 1990; 250: 1593-6.
60. Lambert OM, Petteway SR Jr, McDanal CE. et al, Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells, Antimicrob Agents Chemother 1992; 36: 982-8.
61. Chaudhary VK, Mizukami T, Fuerst TR, et al, Selective killing ofHIVinfected cells by recombinant human CD4-Pseudol1lonas exotoxin hybrid protein, Nature 1988; 335: 369-72.
62. Till MA, Ghetie V, Gregory T, et al, HIV-infected cells are killed by CD4-ricin A chain, Science 1988; 242: 1166-8.
63. Ashorn P, Englund G, Martin MA, Moss B, Berger EA, Anti-HIV activity of CD4-Pseudolllonas exotoxin on infected primary human lymphocytes and monocyte/rnacrophages, J Infect Dis 1991; 163: 703-9.